Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Account Payables (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Change in Account Payables readings, the most recent being $510000.0 for Q1 2026.

  • On a quarterly basis, Change in Account Payables rose 117.1% to $510000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$747000.0, a 49.18% increase, with the full-year FY2025 number at -$4.2 million, down 717.18% from a year prior.
  • Change in Account Payables hit $510000.0 in Q1 2026 for Atara Biotherapeutics, up from -$191000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.5 million in Q3 2023 to a low of -$4.6 million in Q1 2022.
  • Median Change in Account Payables over the past 5 years was -$894000.0 (2023), compared with a mean of -$904941.2.
  • Biggest five-year swings in Change in Account Payables: soared 368.34% in 2024 and later plummeted 261.14% in 2025.
  • Atara Biotherapeutics' Change in Account Payables stood at -$4.5 million in 2022, then surged by 36.85% to -$2.8 million in 2023, then skyrocketed by 179.12% to $2.2 million in 2024, then tumbled by 108.59% to -$191000.0 in 2025, then soared by 367.02% to $510000.0 in 2026.
  • The last three reported values for Change in Account Payables were $510000.0 (Q1 2026), -$191000.0 (Q4 2025), and -$983000.0 (Q3 2025) per Business Quant data.